Grand challenges in the immunology of HIV and AIDS

Frontiers in Immunology

Volumn 2, Issue SEP, 2011, Pages

  Miedema, Frank ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874049917     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2011.00020     Document Type: Article

References (41)

1. Autran, B., Murphy, R. L., Costagliola, D., Tubiana, R., Clotet, B., Gatell, J., Staszewski, S., Wincker, N., Assoumou, L., El-Habib, R., Calvez, V., Walker, B., Katlama, C., and ORVACS Study Group. (2008). Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immuniza- tion with the ALVAC-HIV vaccine (vCP1452). AIDS 22, 1313-1322.
2. Beignon, A. S., McKenna, K., Skoberne, M., Manches, O., DaSilva, I., Kavanagh, D. G., Larsson, M., Gorelick, R. J., Lifson, J. D., and Bhardwaj, N. (2005). Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J. Clin. Invest. 115, 3265-3275.
3. Betts, M. R., Nason, M. C., West, S. M., De Rosa, S. C., Migueles, S. A., Abraham, J., Lederman, M. M., Benito, J. M., Goepfert, P. A., Connors, M., Roederer, M., and Koup, R. A. (2006). HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107, 4781-4789.
4. Bosinger, S. E., Li, Q., Gordon, S. N., Klatt, N. R., Duan, L., Xu, L., Francella, N., Sidahmed, A., Smith, A. J., Cramer, E. M., Zeng, M., Masopust, D., Carlis, J. V., Ran, L., Vanderford, T. H., Paiardini, M., Isett, R. B., Baldwin, D. A., Else, J. G., Staprans, S. I., Silvestri, G., Haase, A. T., and Kelvin, D. J. (2009). Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J. Clin. Invest. 119, 3556-3572.
5. Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., and Louis, T. A. (2003). Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N. Engl. J. Med. 348, 702-710.
6. Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, S., Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., Blazar, B. R., Rodriguez, B., Teixeira-Johnson, L., Landay, A., Martin, J. N., Hecht, F. M., Picker, L. J., Lederman, M. M., Deeks, S. G., and Douek, D. C. (2006). Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371.
7. Bunnik, E. M., Euler, Z., Welkers, M. R., Boeser-Nunnink, B. D., Grijsen, M. L., Prins, J. M., and Schuitemaker, H. (2010). Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. Nat. Med. 16, 995-997.
8. Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and Lusso, P. (1995). Identification of RANTES, MIP-1a, and MIP-1b as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811-1815.
9. Connor, R. I., Sheridan, K. E., Ceradini, D., Choe, S., and Landau, N. R. (1997). Change in coreceptor use correlates w0ith disease progression in HIV-1-infected individuals. J. Exp. Med. 185, 621-628.
10. Deeks, S. G. (2011). HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62, 141-155.
11. Deeks, S. G., Kitchen, C. M., Liu, L., Guo, H., Gascon, R., Narváez, A. B., Hunt, P., Martin, J. N., Kahn, J. O., Levy, J., McGrath, M. S., and Hecht, F. M. (2004). Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 104, 942-947.
12. Douek, D. C., Picker, L. J., and Koup, R. A. (2003). T cell dynamics in HIV-1 infection 14. Annu. Rev. Immunol. 21, 265-304.
13. El-Sadr, W. M. Lundgren, J. D., Neaton, J. D., Gordin, F., Abrams, D., Arduino, R. C., Babiker, A., Burman, W., Clumeck, N., Cohen, C. J., Cohn, D., Cooper, D., Darbyshire, J., Emery, S., Fätkenheuer, G., Gazzard, B., Grund, B., Hoy, J., Klingman, K., Losso, M., Markowitz, N., Neuhaus, J., Phillips, A., and Rappoport, C. (2006). CD4+ count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296.
14. Euler, Z., van Gils, M. J., Bunnik, E. M., Phung, P., Schweighardt, B., Wrin, T., and Schuitemaker, H. (2010). Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201, 1045-1053.
15. Fahey, J. L., Taylor, J. M., Detels, R., Hofmann, B., Melmed, R., Nishanian, P., and Giorgi, J. V. (1990). The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N. Engl. J. Med. 322, 166-172.
16. Fauci, A. S., Pantaleo, G., Stanley, S., and Weissman, D. (1996). Immunopathogenic mechanisms of HIV infection. Ann. Intern. Med. 124, 654-663.
17. Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-877.
18. Fischer, W. Ganusov, V. V., Giorgi, E. E., Hraber, P. T., Keele, B. F., Leitner, T., Han, C. S., Gleasner, C. D., Green, L., Lo, C. C., Nag, A., Wallstrom, T. C., Wang, S., McMichael, A. J., Haynes, B. F., Hahn, B. H., Perelson, A. S., Borrow, P., Shaw, G. M., Bhattacharya, T., and Korber, B. T. (2010). Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS ONE 5, e12303. doi: 10.1371/journal.pone.0012303
19. Frater, A. J., Brown, H., Oxenius, A., Günthard, H. F., Hirschel, B., Robinson, N., Leslie, A. J., Payne, R., Crawford, H., Prendergast, A., Brander, C., Kiepiela, P., Walker, B. D., Goulder, P. J., and McLean, A, Phillips, R. E. (2007). Effective T-cell responses select human immunodeficiency virus mutants and slow disease progression. J. Virol. 81, 6742-6751.
20. Giorgi, J. V., Hultin, L. E., McKeating, J. A., Johnson, T. D., Owens, B., Jacobson, L. P., Shih, R., Lewis, J., Wiley, D. J., Phair, J. P., Wolinsky, S. M., and Detels, R. (1999). Shorter survival in advanced uman immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179, 859-870.
21. Goonetilleke, N., Liu, M. K., Salazar-Gonzalez, J. F., Ferrari, G., Giorgi, E., Ganusov, V. V., Keele, B. F., Learn, G. H., Turnbull, E. L., Salazar, M. G., Weinhold, K. J., Moore, S., CHAVI Clinical Core B, Letvin, N., Haynes, B. F., Cohen, M. S., Hraber, P., Bhattacharya, T., Borrow, P., Perelson, A. S., Hahn, B. H., Shaw, G. M., Korber, B. T., and McMichael, A. J. (2009). The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206, 1253-1272.
22. Grossman, Z., Meier-Schellersheim, M., Sousa, A. E., Victorino, R. M. M., and Paul, W. E. (2002). CD4 T-cell depletion in HIV infection: are we closer to understanding the cause ? Nat. Med. 8, 319-323.
23. Hansen, S. G. Ford, J. C., Lewis, M. S., Ventura, A. B., Hughes, C. M., Coyne-Johnson, L., Whizin, N., Oswald, K., Shoemaker, R., Swanson, T., Legasse, A. W., Chiuchiolo, M. J., Parks, C. L., Axthelm, M. K., Nelson, J. A., Jarvis, M. A., Piatak, M. Jr., Lifson, J. D., and Picker, L. J. (2011). Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527.
24. Hardy, A. W., Graham, D. R., Shearer, G. M., and Herbeuval, J. P. (2007). HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-alpha. Proc. Natl. Acad. Sci. U.S.A. 104, 17453-17458.
25. Hazenberg, M. D., Hamann, D., Schuitemaker, H., and Miedema, F. (2000). T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat. Immunol. 1, 285-289.
26. Hazenberg, M. D., Otto, S. A, van Benthem, B. H., Roos, M. T., Coutinho, R. A., Lange, J. M., Hamann, D., Prins, M., and Miedema, F. (2003). Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17, 1881-1888.
27. Ho, D. D., Neumann, A. U., Perelson, A. S., Chen, W., Leonard, J. M., and Markowitz, M. (1995). Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection. Nature 373, 123-126.
28. Jiang, W., Lederman, M. M., Hunt, P., Sieg, S. F., Haley, K., Rodriguez, B., Landay, A., Martin, J., Sinclair, E., Asher, A. I., Deeks, S. G., Douek, D. C., and Brenchley, J. M. (2009). Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J. Infect. Dis. 199, 1177-1185.
29. Koot, M., Keet, I. P., Vos, A. H., de Goede, R. E., Roos, M. T., Coutinho, R. A., Miedema, F., Schellekens, P. T., and Tersmette, M. (1993). Prognostic value of human immunodeficiency virus type 1 biological phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118, 681-688.
30. Leslie, A. J., and Goulder, P. J. (2006). HIV escape and attenuation by cytotoxic T lymphocytes. Curr. Opin. HIV AIDS 1, 34-39.
31. McCune, J. M. (2001). The dynamics of CD4+ T-cell depletion in HIV disease. Nature 410, 974-979.
32. Medzhitov, R. (2010). Inflammation 2010: new adventures of an old flame. Cell 140, 771-776.
33. Meier, A., Alter, G., Frahm, N., Sidhu, H., Li, B., Bagchi, A., Teigen, N., Streeck, H., Stellbrink, H. J., Hellman, J., van Lunzen, J., and Altfeld, M. (2007). MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands. J. Virol. 81, 8180-8191.
34. Miura, T., Brumme, Z. L., Brockman, M. A., Rosato, P., Sela, J., Brumme, C. J., Pereyra, F., Kaufmann, D. E., Trocha, A., Block, B. L., Daar, E. S., Connick, E., Jessen, H., Kelleher, A. D., Rosenberg, E., Markowitz, M., Schafer, K., Vaida, F., Iwamoto, A., Little, S., and Walker, BD. (2010). Impaired replication capacity of acute/early viruses in persons who become HIV controllers. J. Virol. 84, 7581-7591.
35. Navis, M., Schellens, I., van Baarle, D., Borghans, J., van Swieten, P., Miedema, F., Kootstra, N., and Schuitemaker, H. (2007). Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J. Immunol. 179, 3133-3143.
36. Schellens, I. M., Borghans, J. A., Jansen, C. A., De Cuyper, I. M., Geskus, R. B., van Baarle, D., and Miedema, F. (2008). Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time. PLoS ONE 3, e2745. doi: 10.1371/journal. pone.0002745
37. Sereti, I., Dunham, R. M., Spritzler, J., Aga, E., Proschan, M. A., Medvik, K., Battaglia, C. A., Landay, A. L., Pahwa, S., Fischl, M. A., Asmuth, D. M., Tenorio, A. R., Altman, J. D., Fox, L., Moir, S., Malaspina, A., Morre, M., Buffet, R., Silvestri, G., and Lederman, M. M., ACTG 5214 Study Team. (2009). IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 113, 6304-6314.
38. Silvestri, G., Sodora, D. L., Koup, R. A., Paiardini, M., O'Neil, S. P., McClure, H. M., Staprans, S. I., and Feinberg, M. B. (2003). Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic highlevel viremia. Immunity 18, 441-452.
39. Tersmette, M., Gruters, R. A., de Wolf, F., de Goede, R. E., Lange, J. M., Schellekens, P. T., Goudsmit, J., Huisman, H. G., and Miedema, F. (1989). Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J. Virol. 63, 2118-2125.
40. Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., Longo, N. S., McKee, K., O'Dell, S., Louder, M. K., Wycuff, D. L., Feng, Y., Nason, M., Doria-Rose, N., Connors, M., Kwong, P. D., Roederer, M., Wyatt, R. T., Nabel, G. J., and Mascola, J. R. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856-861.
41. Zhou, T., Georgiev, I., Wu, X., Yang, Z. Y., Dai, K., Finzi, A., Kwon, Y. D., Scheid, J. F., Shi, W., Xu, L., Yang, Y., Zhu, J., Nussenzweig, M. C., Sodroski, J., Shapiro, L., Nabel, G. J., Mascola, J. R., and Kwong, P. D. (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811-817.